DALLAS/FORT WORTH, Texas, July 23, 2015 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. ("Neos" or "the Company") today announced the pricing of its initial public offering of 4,800,000 shares of common stock at an initial public offering price of $15.00 per share. In addition, Neos has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock at the initial public offering price. The shares of Neos' common stock are expected to begin trading on the NASDAQ Global Market on July 23, 2015 under the ticker symbol "NEOS." The offering is expected to close on July 28, 2015, subject to customary closing conditions.
UBS Investment Bank, BMO Capital Markets and RBC Capital Markets are acting as joint book-running managers and JMP Securities is acting as a lead manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 22, 2015. The offering will be made only by means of a prospectus, copies of which may be obtained from the offices of UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, or by telephone: (888) 827-7275; BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, Telephone: (800) 414-3627, Email: email@example.com; or RBC Capital Markets, LLC, Attention: Prospectus Department, 200 Vesey Street, 8th Floor, New York, NY 10281.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platform. The Company is initially focusing on ADHD and has developed three branded product candidates that are XR medications in patient-friendly ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
Vipin Garg, Chief Executive Officer, President and Director Neos Therapeutics (919) 434-6643 firstname.lastname@example.org Richard I. Eisenstadt, Chief Financial Officer Neos Therapeutics (972) 408-1389 email@example.com David Carey, Investor Relations Lazar Partners (212) 867-1768 firstname.lastname@example.org